Yasuhiko Kamikubo

11PUBLICATIONS
38CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCellular nervous systemGenome structure and regulation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Dec 26, 2022
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.

Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani

|Sep 09, 2022
A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice.

Etsuko Yamamoto Hattori, Tatsuya Masuda, Yohei Mineharu

|Jul 18, 2022
RUNX inhibitor suppresses graft-versus-host disease through targeting RUNX-NFATC2 axis.

Hirohito Kubota, Tatsuya Masuda, Mina Noura

|Dec 13, 2021
RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.

Tatsuya Masuda, Shintaro Maeda, Sae Shimada

Pageof 2